Recommendations for the Clinical Management of Hepatitis C in Iran: A Consensus-Based National Guideline

Abstract

ContextHepatitis C virus (HCV) infection is a major public health issue worldwide, including Iran. The new direct-acting antiviral agents (DAAs) with high efficacy have changed the landscape of HCV treatment. This guideline provides updated recommendations for clinical management of HCV infection in Iran.Evidence AcquisitionThe recommendations of this guideline are based on international and national scientific evidences and consensus-based expert opinion. Scientific evidences were collected through a systematic review of studies that evaluated efficacy and safety of DAA regimens, using PubMed, Scopus and Web of Science. Expert opinion was based on the consensus of Iran Hepatitis Scientific Board (IHSB) in the 3rd national consensus on management of Hepatitis C in Iran, held on 22nd of July 2016.ResultsPegylated Interferon alpha (PegIFN), Ribavirin (RBV), Sofosbuvir (SOF), Ledipasvir (LDV) and Daclatasvir (DCV) are currently available in Iran. Pre-treatment assessments include HCV RNA level, HCV genotype and resistance testing, assessment of liver fibrosis, and underlying diseases. In HCV genotype 1 and 4, DCV/SOF and LDV/SOF are recommended. In HCV genotype 2, SOF plus RBV and in HCV genotype 3, DCV/SOF is recommended. Additional care for underlying diseases should be considered.ConclusionsAffordable new HCV treatment regimens are available in Iran, providing an opportunity for HCV elimination. Recommendations provided in this current national guideline can facilitate evidence-based management of HCV infection.

Seroprevalence of Hepatitis C Virus among Blood Donors in Middle Eastern Countries: A Systematic Review and Meta-Analysis

“…These new therapies resulting in more than 95% treatment success have made hepatitis C a curable infectious disease (71)(72)(73). With availability of efficient treatments for hepatitis C, there is great hope to eliminate this disease by 2030; however, prevention of hepatitis C transmission through blood and blood products has a key role in elimination programs, as well (69).…”

Update on the Prevalence of Hepatitis C Virus Infection Among Iranian General Population: A Systematic Review and Meta-Analysis

“…2017; 17(2):e42291. HCV elimination could be an achievable goal in Iran provided that required financial investments for increasing awareness about HCV, early diagnosis, and treatment of infected patients are met (27,28).…”

Research progress on the direct antiviral drugs for hepatitis C virus

“…This regimen has been mainly used for the treatment of patients infected with HCV genotype 1 (subtypes 1a and 1b) and 4. The daclatasvir and sofosbuvir combination regimen was approved by the European medicine agency for treatment of genotype 1-4 infections in 2014, followed by the FDA for treatment of genotypes 1 and 3 (32). According to several meta-analyses that analyzed the efficacy of this regimen on different genotypes, daclatasvir/sofosbuvir with and without ribavirin can be considered as a highly useful treatment option in treatment-naïve or treatment-experienced patients with genotype 1 and 3 infections with and without cirrhosis (31,33).…”